Axovant Sciences Ltd (AXON) Rating Lowered to Sell at BidaskClub
BidaskClub downgraded shares of Axovant Sciences Ltd (NYSE:AXON) from a hold rating to a sell rating in a research note published on Tuesday morning.
A number of other research firms have also recently issued reports on AXON. Cowen and Company restated an outperform rating and set a $30.00 target price on shares of Axovant Sciences in a research note on Wednesday, June 21st. Jefferies Group LLC started coverage on shares of Axovant Sciences in a research note on Monday, July 10th. They issued a buy rating and a $40.00 price objective for the company. HC Wainwright reiterated a buy rating and issued a $11.00 price objective on shares of Axovant Sciences in a research note on Wednesday, September 27th. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $30.00 price objective on shares of Axovant Sciences in a research note on Monday, September 25th. Finally, Evercore ISI reiterated an outperform rating and issued a $9.00 price objective (down previously from $30.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Hold and an average target price of $14.13.
Axovant Sciences (AXON) opened at 5.68 on Tuesday. The company’s market cap is $610.74 million. Axovant Sciences has a 12-month low of $5.51 and a 12-month high of $27.98. The stock’s 50 day moving average is $13.71 and its 200 day moving average is $19.92.
Axovant Sciences (NYSE:AXON) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). On average, equities analysts forecast that Axovant Sciences will post ($2.02) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/21/axovant-sciences-ltd-axon-rating-lowered-to-sell-at-bidaskclub.html.
A number of institutional investors have recently modified their holdings of AXON. FMR LLC raised its stake in Axovant Sciences by 968.5% in the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares in the last quarter. Janus Henderson Group PLC bought a new position in Axovant Sciences in the 2nd quarter valued at about $47,854,000. Capital Research Global Investors increased its holdings in Axovant Sciences by 21.8% in the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after buying an additional 619,226 shares during the period. Point72 Asset Management L.P. increased its holdings in Axovant Sciences by 1,718.3% in the 1st quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock valued at $3,124,000 after buying an additional 197,600 shares during the period. Finally, State Street Corp increased its holdings in Axovant Sciences by 52.8% in the 2nd quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after buying an additional 188,945 shares during the period.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.